Moderna (MRNA)
(Delayed Data from NSDQ)
$107.97 USD
+1.79 (1.69%)
Updated Apr 26, 2024 03:59 PM ET
Pre-Market: $108.01 +0.04 (0.04%) 8:46 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNA 107.97 +1.79(1.69%)
Will MRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Other News for MRNA
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2024
Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more
All In on Microsoft Stock: How AI Turned MSFT Into the Hottest Tech Play of 2024
WHO picks JN.1 variant for next set of COVID vaccines